Paricalcitol Reduces Oxidative Stress and Inflammation in Hemodialysis Patients

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2012 Nov 29

PMID 23186077

Citations 29

Authors

Maria Jesus Izquierdo

Monica Cavia

Pilar Muniz

Angel L M de Francisco

Manuel Arias

Javier Santos

Pedro Abaigar

Affiliations

Soon will be listed here.

Abstract

Background: Treatment with selective vitamin D receptor activators such as paricalcitol have been shown to exert an anti-inflammatory effect in patients on hemodialysis, in addition to their action on mineral metabolism and independently of parathyroid hormone (PTH) levels. The objective of this study was to evaluate the additional antioxidant capacity of paricalcitol in a clinical setting.

Methods: The study included 19 patients with renal disease on hemodialysis, of whom peripheral blood was obtained for analysis at baseline and three months after starting intravenous paricalcitol treatment. The following oxidizing and inflammatory markers were quantified: malondialdehyde (MDA), nitrites and carbonyl groups, indoleamine 2,3-dioxygenase (IDO), tumor necrosis factor alfa (TNF-α), interleukin-6 (IL-6), interleukin-18 (IL-18) and C-reactive protein (CRP). Of the antioxidants and anti-inflammatory markers, superoxide dismutase (SOD), catalase, reduced glutathione (GSH), thioredoxin, and interleukin-10 (IL-10) levels were obtained.

Results: Baseline levels of oxidation markers MDA, nitric oxide and protein carbonyl groups significantly decreased after three months on paricalcitol treatment, while levels of GSH, thioredoxin, catalase and SOD activity significantly increased. After paricalcitol treatment, levels of the inflammatory markers CRP, TNF-α, IL-6 and IL-18 were significantly reduced in serum and the level of anti-inflammatory cytokine IL-10 was increased.

Conclusions: In renal patients undergoing hemodialysis, paricalcitol treatment significantly reduces oxidative stress and inflammation, two well known factors leading to cardiovascular damage.

Citing Articles

Combination Therapy with Enalapril and Paricalcitol Ameliorates Streptozotocin Diabetes-Induced Testicular Dysfunction in Rats via Mitigation of Inflammation, Apoptosis, and Oxidative Stress.

Elsaeed M, Mehanna O, Abd-Allah E, Hassan M, Ahmed W, Moustafa A Pathophysiology. 2023; 30(4):567-585.

PMID: 38133142 PMC: 10747062. DOI: 10.3390/pathophysiology30040041.

Vitamin D deficiency in dengue fever patients' coinfected with in Pakistan. A case-control study.

Mirza W, Zhang K, Zhang R, Duan G, Nawaz Khan M, Ni P Front Public Health. 2022; 10:1035560.

PMID: 36388314 PMC: 9659955. DOI: 10.3389/fpubh.2022.1035560.

Paricalcitol protects against hydrogen peroxide-induced injury in endothelial cells through suppression of apoptosis.

Koksal M, Sekerler T, Cevik O, Sener A Exp Biol Med (Maywood). 2022; 248(2):186-192.

PMID: 36373746 PMC: 10041050. DOI: 10.1177/15353702221101615.

Calcitriol Treatment Attenuates Uric Acid-Induced Kidney Injury via Super Oxide Dismutase-1 (SOD-1) Upregulation and Fibrosis Reduction.

Romi M, Arefian N, Setyaningsih W, Putri R, Juffrie M, Sari D Iran Biomed J. 2021; 25(6):417-25.

PMID: 34641645 PMC: 8744697. DOI: 10.52547/ibj.25.6.417.

Paricalcitol Improves Hypoxia-Induced and TGF-β1-Induced Injury in Kidney Pericytes.

Lim J, Yook J, Oh S, Jeon S, Noh H, Jung H Int J Mol Sci. 2021; 22(18).

PMID: 34575914 PMC: 8472327. DOI: 10.3390/ijms22189751.

References

McCord J, Fridovich I . Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem. 1969; 244(22):6049-55. View

Pawlak K, Brzosko S, Mysliwiec M, Pawlak D . Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis. 2008; 204(2):561-6. DOI: 10.1016/j.atherosclerosis.2008.10.002. View

Brigelius R, Muckel C, Akerboom T, Sies H . Identification and quantitation of glutathione in hepatic protein mixed disulfides and its relationship to glutathione disulfide. Biochem Pharmacol. 1983; 32(17):2529-34. DOI: 10.1016/0006-2952(83)90014-x. View

Sprague S, Llach F, Amdahl M, Taccetta C, Batlle D . Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 63(4):1483-90. DOI: 10.1046/j.1523-1755.2003.00878.x. View

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

Levin A, Li Y . Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?. Kidney Int. 2005; 68(5):1973-81. DOI: 10.1111/j.1523-1755.2005.00651.x. View

Morena M, Cristol J, Canaud B . Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro/antioxidant imbalance. Blood Purif. 2000; 18(3):191-9. DOI: 10.1159/000014418. View

Lund R, Andress D, Amdahl M, Williams L, Heaney R . Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol. 2009; 31(2):165-70. DOI: 10.1159/000266204. View

Wu C, Chang J, Chen C, Su S, Yang L, Ma W . Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med. 2011; 223(3):153-9. DOI: 10.1620/tjem.223.153. View

10.

Mittman N, Desiraju B, Meyer K, Chattopadhyay J, Avram M . Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Kidney Int Suppl. 2010; (117):S33-6. DOI: 10.1038/ki.2010.191. View

11.

Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E . Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol. 2008; 29(5):465-72. DOI: 10.1159/000178251. View

12.

Mathew S, Lund R, Chaudhary L, Geurs T, Hruska K . Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008; 19(8):1509-19. PMC: 2488263. DOI: 10.1681/ASN.2007080902. View

13.

Takeda M, Yamashita T, Sasaki N, Nakajima K, Kita T, Shinohara M . Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler Thromb Vasc Biol. 2010; 30(12):2495-503. DOI: 10.1161/ATVBAHA.110.215459. View

14.

Handelman G . Evaluation of oxidant stress in dialysis patients. Blood Purif. 2000; 18(4):343-9. DOI: 10.1159/000014460. View

15.

Chugh S, Jain S, Agrawal N, Sharma A . Evaluation of oxidative stress before and after haemodialysis in chronic renal failure. J Assoc Physicians India. 2001; 48(10):981-4. View

16.

Guillot X, Semerano L, Saidenberg-Kermanach N, Falgarone G, Boissier M . Vitamin D and inflammation. Joint Bone Spine. 2010; 77(6):552-7. DOI: 10.1016/j.jbspin.2010.09.018. View

17.

Lindberg J, Martin K, Gonzalez E, Acchiardo S, Valdin J, Soltanek C . A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol. 2001; 56(4):315-23. View

18.

Finch J, Suarez E, Husain K, Ferder L, Cardema M, Glenn D . Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Am J Physiol Renal Physiol. 2011; 302(1):F141-9. DOI: 10.1152/ajprenal.00293.2011. View

19.

Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C . Vitamin D: modulator of the immune system. Curr Opin Pharmacol. 2010; 10(4):482-96. DOI: 10.1016/j.coph.2010.04.001. View

20.

Dirican M, Sarandol E, Serdar Z, Ocak N, Dilek K . Oxidative status and prevalent cardiovascular disease in patients with chronic renal failure treated by hemodialysis. Clin Nephrol. 2007; 68(3):144-50. DOI: 10.5414/cnp68144. View